

May 26, 2022

Kidswell Bio Corporation

Code: 4584 (TSE Mothers)

Masaharu Tani, President & CEO

Announcement of research collaboration agreement with
Chiome Bioscience Inc. for the development of antibody drugs
(Extracted from Japanese version)

Tokyo, May 26, 2022 – Kidswell Bio Corporation (KWB) executed a research collaboration agreement with Chiome Bioscience Inc. (Chiome) on May 26, 2022 for accelerating the antibody-drug research in the oncology field by the combining knowledge and technologies of KWB and Chiome.

Chiome, as a drug discovery and drug discovery support company in the antibody drugs field, has various technologies, systems, and know-how required for the development of antibody drugs. In addition, Chiome is currently conducting a clinical trial of antibody in the oncology field that has been internally developing.

As explained in the medium-term strategic plan, KWB2.0, announced on May 12, 2022, KWB has been promoting research and development in the cell therapy business (regenerative medicine) and new biologics business as important future growth drivers while strengthening KWB's stable business foundation of the biosimilars business. KWB believes that research collaboration with Chiome will accelerate research of KWB's new biologics business that is one of KWB's growth drivers. KWB will continue to discuss possible collaboration scheme with Chiome assuming that the research collaboration at this time successfully move forward to the next stage where a candidate antibody will be regarded as a development pipeline. Furthermore, KWB will continue to strive to create new medical treatments and maximize KWB's corporate value.

The impact on the business results for the fiscal year ending March 2023 is expected to be minimal.

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children's potential vital force such as SHED, stem cell from exfoliated deciduous teeth, we envision creating new pharmaceuticals and therapeutics for all people under "Kids Well, All Well."

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com